Deutsche Bank AG Makes New $39.84 Million Investment in Intelligent Bio Solutions Inc. $INBS

Deutsche Bank AG acquired a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 7,721,585 shares of the company’s stock, valued at approximately $39,843,000. Deutsche Bank AG owned 322.81% of Intelligent Bio Solutions at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in INBS. Bank of New York Mellon Corp purchased a new stake in Intelligent Bio Solutions in the second quarter worth about $9,655,000. Alyeska Investment Group L.P. lifted its stake in shares of Intelligent Bio Solutions by 9.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 673,492 shares of the company’s stock valued at $687,000 after purchasing an additional 59,600 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Intelligent Bio Solutions during the third quarter valued at approximately $435,000. State of Wyoming purchased a new stake in Intelligent Bio Solutions in the second quarter worth $453,000. Finally, GSA Capital Partners LLP purchased a new stake in Intelligent Bio Solutions in the second quarter worth $184,000. 32.97% of the stock is currently owned by institutional investors.

Intelligent Bio Solutions Stock Performance

INBS opened at $2.51 on Friday. The company’s 50-day simple moving average is $2.19 and its two-hundred day simple moving average is $3.05. The stock has a market capitalization of $6.00 million, a P/E ratio of -0.28 and a beta of 4.21. Intelligent Bio Solutions Inc. has a 52-week low of $1.52 and a 52-week high of $24.90.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.68. Intelligent Bio Solutions had a negative return on equity of 175.35% and a negative net margin of 294.88%.The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $1.22 million. Research analysts forecast that Intelligent Bio Solutions Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Friday, July 17th. Zacks Research upgraded shares of Intelligent Bio Solutions to a “hold” rating in a report on Monday, June 29th. Finally, Wall Street Zen cut Intelligent Bio Solutions from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Intelligent Bio Solutions presently has a consensus rating of “Reduce”.

About Intelligent Bio Solutions

Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.